Literature DB >> 6313523

Influence of an angiotensin converting-enzyme inhibitor on diuretic-induced metabolic effects in hypertension.

M H Weinberger.   

Abstract

Diuretic therapy is frequently accompanied by undesirable biochemical changes and side-effects. Two multicenter trials compared the effects of captopril combined with a diuretic to the administration of either agent alone in mild-to-moderate hypertensives. In addition to blood pressure, effects on serum potassium, uric acid, glucose, and cholesterol were examined. The first study (Study A) was conducted on 210 such patients randomly assigned to receive: 1) hydrochlorothiazide (H) 15 mg three times daily (t.i.d.); 2) captopril (C) 25 mg t.i.d.; or 3) C + H for 6 weeks. The second study (Study B) involved 415 patients randomly assigned to receive: 1) C 25 mg twice daily (b.i.d.) + H 25 mg b.i.d.; 2) C 50 mg b.i.d. + H 25 mg b.i.d.; 3) C 50 mg b.i.d. + placebo b.i.d.; 4) placebo b.i.d. + H 25 mg b.i.d.; or 5) placebo b.i.d. + placebo b.i.d. for 6 weeks. In both Studies A and B, all patients except those receiving placebo only (Study B-5) had significant (p less than 0.05) blood pressure reductions. In Study A, the combination of C + H (A-3) produced a significantly greater (p less than 0.001) reduction in blood pressure than either agent alone. In Study B, both C + H groups (B-1, B-2) had a significantly greater (p less than 0.01) blood pressure reduction than that seen with C alone (B-3). In Study A, those treated with H alone (A-1) had a significant (p less than 0.05) reduction in serum potassium and increases in uric acid, glucose, and cholesterol when compared to C alone (A-2) where no changes in these parameters were observed.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6313523     DOI: 10.1161/01.hyp.5.5_pt_2.iii132

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  18 in total

Review 1.  Is fixed combination therapy appropriate for initial hypertension treatment?

Authors:  William J Elliott
Journal:  Curr Hypertens Rep       Date:  2002-08       Impact factor: 5.369

Review 2.  ACE inhibitors compared with thiazide diuretics as first-step antihypertensive therapy.

Authors:  I J Perry; D G Beevers
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

3.  ADDRESSING HYPERTENSION IN THE PATIENT WITH TYPE 2 DIABETES MELLITUS: PATHOGENESIS, GOALS, AND THERAPEUTIC APPROACH.

Authors:  Ali A Rizvi
Journal:  Eur Med J Diabetes       Date:  2017-10

4.  [Results of a 5-year study with captopril in patients with severe therapy-resistant hypertension].

Authors:  J Schrader; G Schoel; F Scheler
Journal:  Klin Wochenschr       Date:  1986-08-01

Review 5.  Serum lipoproteins during treatment with antihypertensive drugs.

Authors:  P Weidmann; C Ferrier; H Saxenhofer; D E Uehlinger; B N Trost
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 6.  Drug-induced taste and smell disorders. Incidence, mechanisms and management related primarily to treatment of sensory receptor dysfunction.

Authors:  R I Henkin
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

Review 7.  Adverse metabolic effects of antihypertensive drugs. Implications for treatment.

Authors:  H G Preuss; J F Burris
Journal:  Drug Saf       Date:  1996-06       Impact factor: 5.606

8.  A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia.

Authors:  U Hauf-Zachariou; L Widmann; B Zülsdorf; M Hennig; P D Lang
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 9.  Pharmacokinetic drug interactions with ACE inhibitors.

Authors:  H Shionoiri
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

Review 10.  Adverse effects of angiotensin converting enzyme (ACE) inhibitors. An update.

Authors:  R C Parish; L J Miller
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.